The effect of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene E4 after ascent to high altitude

Chest

Volumn 127, Issue 2, 2005, Pages 565-570

  Grissom, Colin K ^a   Richer, Lori D ^b   Elstad, Mark R ^c  

^a LDS HOSPITAL   (United States)

^b New Hampshire Dartmouth Psychiatric Research Center   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acute mountain sickness; High altitude; Urinary leukotriene E4; Zileuton

Indexed keywords

CREATININE; LEUKOTRIENE E4; LIPOXYGENASE INHIBITOR; PLACEBO; ZILEUTON; ARACHIDONATE 5 LIPOXYGENASE; AUTACOID; DRUG DERIVATIVE; HYDROXYUREA;

ADULT; ALTITUDE; ALTITUDE DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LUNG EDEMA; MALE; PRIORITY JOURNAL; PROPHYLAXIS; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL; SEA LEVEL; STATISTICAL ANALYSIS; UNITED STATES; URINALYSIS; ACCLIMATIZATION; BLOOD; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; MIDDLE AGED; MOUNTAINEERING; ORAL DRUG ADMINISTRATION; OXIMETRY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREMEDICATION; STATISTICS; TREATMENT OUTCOME; URINE;

ACCLIMATIZATION; ADMINISTRATION, ORAL; ADULT; ALASKA; ALTITUDE SICKNESS; ARACHIDONATE 5-LIPOXYGENASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYUREA; INFLAMMATION MEDIATORS; LEUKOTRIENE E4; LIPOXYGENASE INHIBITORS; MALE; MIDDLE AGED; MOUNTAINEERING; OXIMETRY; PREMEDICATION; STATISTICS; TREATMENT OUTCOME;

EID: 13644263395     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.2.565     Document Type: Article

References (23)

1. Grissom CK, Schoene RB. Adaptation and maladaptation to high altitude. In: Crapo JD, Glassroth J, Karlinsky J, et al, eds. Baum's textbook of pulmonary diseases, 7th ed. New York, NY: Lippincott, Williams & Wilkins, 2004; 1005-1023
2. 4 levels increase upon exposure to hypobaric hypoxia. Chest 1996; 110:946-951
3. Richalet JP, Hornych A, Rathat C, et al. Plasma prostaglandins, leukotrienes and thromboxane in acute high altitude hypoxia. Respir Physiol 1991; 85:205-215
4. 4 levels at high altitude [abstract]. High Altitude Med Biol 2001; 2:112
5. Muza SR, Kaminsky D, Fulco CS, et al. Cysteinyl leukotriene blockade does not prevent acute mountain sickness. Aviat Space Environ Med 2004; 75:413-419
6. 4 levels in high-altitude pulmonary edema, a possible role for inflammation. Chest 1996; 110:939-945
7. Schoene RB, Swenson ER, Pizzo CJ, et al. The lung at high altitude, bronchoalveolar lavage in acute mountain sickness and pulmonary edema. J Appl Physiol 1988; 64:2605-2613
8. Swenson ER, Maggiorini M, Mongovin S, et al. Pathogenesis of high-altitude pulmonary edema: inflammation is not an etiologic factor. JAMA 2002; 287:2228-2235
9. 4 levels are not increased prior to high altitude pulmonary edema. Chest 2000; 117:1393-1398
10. Roach RC, Bartsch P, Hackett PH, et al. The Lake Louise acute mountain sickness scoring system. In: Sutton JR, Houston CS, Coates G, eds. Hypoxia and molecular medicine. Burlington, VT: Charles S. Houston, 1993; 272-274
11. 4. Prostaglandins Other Lipid Mediators 1998; 55:301-321
12. Wenzel SE, Trudeau JB, Kaminsky DA, et al. Effect of 5-lipoxygnease inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995; 152:897-905
13. Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygnease by zileuton in mild to moderate asthma. Ann Intern Med 1993; 119:1059-1066
14. McEvoy GK, ed. AHFS Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists, 2004; 3661-3662
15. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996; 98:1-13
16. Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323:1740-1744
17. Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial; Zileuton Clinical Trial Group. JAMA 1996; 275:931-936
18. Hui KP, Taylor IK, Taylor GW, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991; 46:184-189
19. Meltzer SS, Hasday JD, Cohn J, et al. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996; 153:931-935
20. Bestle MH, Olsen NV, Poulsen TD, et al. Prolonged hypobaric hypoxemia attenuates vasopressin secretion and renal response to osmostimulation in men. J Appl Physiol 2002; 92:1911-1922
21. Wetter TJ, Xiang Z, Sonetti DA, et al. Role of lung inflammatory mediators as a cause of exercise-induced arterial hypoxemia in young athletes. J Appl Physiol 2002; 93:116-126
22. 4 excretion in exercise-induced asthma. J Appl Physiol 1992; 73:743-748
23. 4 in asthmatic patients. Eur Respir J 1998; 11:617-623